Myriad Genetics, Inc. (NASDAQ:MYGN) has been given an average recommendation of “Hold” by the thirteen brokerages that are presently covering the firm, MarketBeat Ratings reports. Three investment analysts have rated the stock with a sell recommendation, five have given a hold recommendation, three have assigned a buy recommendation and one has given a strong buy recommendation to the company. The average 1 year price target among brokers that have issued a report on the stock in the last year is $37.74.
Several research analysts have weighed in on MYGN shares. Zacks Investment Research cut First Merchants from a “hold” rating to a “sell” rating in a research report on Monday, July 1st. Cowen reaffirmed a “hold” rating on shares of Axovant Gene Therapies in a research report on Tuesday, July 9th. BidaskClub cut Extraction Oil & Gas from a “hold” rating to a “sell” rating in a research report on Saturday, May 4th. ValuEngine cut Valero Energy from a “hold” rating to a “sell” rating in a research report on Wednesday, May 8th. Finally, Barclays set a $18.00 price target on Summit Materials and gave the company a “hold” rating in a research report on Friday, June 14th.
MYGN stock traded up $1.83 during midday trading on Tuesday, hitting $28.51. The company’s stock had a trading volume of 2,310,223 shares, compared to its average volume of 1,006,999. The company’s 50-day moving average is $25.46. The company has a current ratio of 3.15, a quick ratio of 2.86 and a debt-to-equity ratio of 0.24. Myriad Genetics has a 1 year low of $22.07 and a 1 year high of $50.44. The stock has a market cap of $2.09 billion, a PE ratio of 23.76, a price-to-earnings-growth ratio of 1.59 and a beta of 0.82.
Several hedge funds and other institutional investors have recently modified their holdings of the company. Baillie Gifford & Co. lifted its position in shares of Myriad Genetics by 0.6% during the 1st quarter. Baillie Gifford & Co. now owns 9,540,586 shares of the company’s stock valued at $316,747,000 after buying an additional 55,642 shares during the last quarter. D. E. Shaw & Co. Inc. lifted its holdings in Myriad Genetics by 0.8% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 3,922,852 shares of the company’s stock worth $114,037,000 after purchasing an additional 29,874 shares in the last quarter. Frontier Capital Management Co. LLC lifted its holdings in Myriad Genetics by 4.4% during the 1st quarter. Frontier Capital Management Co. LLC now owns 3,363,970 shares of the company’s stock worth $111,684,000 after purchasing an additional 140,404 shares in the last quarter. Northern Trust Corp lifted its holdings in Myriad Genetics by 2.1% during the 4th quarter. Northern Trust Corp now owns 1,692,079 shares of the company’s stock worth $49,189,000 after purchasing an additional 34,066 shares in the last quarter. Finally, Norges Bank purchased a new stake in Myriad Genetics during the 4th quarter worth about $33,803,000. 99.22% of the stock is currently owned by hedge funds and other institutional investors.
About Myriad Genetics
Myriad Genetics, Inc, a molecular diagnostic company, focuses on developing and marketing novel predictive medicine, personalized medicine, and prognostic medicine tests worldwide. The company offers molecular diagnostic tests, including myRisk Hereditary Cancer, a DNA sequencing test for hereditary cancers; BRACAnalysis, a DNA sequencing test to assess the risk of developing breast and ovarian cancer; BRACAnalysis CDx, a DNA sequencing test for use as a companion diagnostic with the platinum based chemotherapy agents and poly ADP ribose inhibitor Lynparza; riskScore, a clinically validated personalized medicine tool; GeneSight, a DNA genotyping test to optimize psychotropic drug selection for neuroscience patients; and Tumor BRACAnalysis CDx, a DNA sequencing test that is designed to be utilized to predict response to DNA damaging agents.
Read More: How to start trading in the forex market?
Receive News & Ratings for Myriad Genetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Myriad Genetics and related companies with MarketBeat.com's FREE daily email newsletter.